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INTRODUCTION
Mycophenolic acid (MPA) acts via inhibition of inosine monophosphate dehydrogenase (IMPDH) and forms part of the triple immunosuppressive therapy for transplant recipients. In humans, MPA is metabolised primarily by glucuronidation in the liver (Bowalgaha and Miners, 2001 ) to form mycophenolate ether glucuronide (MPAGe) and mycophenolate acyl glucuronide (MPAGa) . MPAGe has no inhibitory effects on IMPDH (Schutz et al., 1999) and is the major urinary excretion product of MPA accounting for >95% of the administered dose (Bullingham et al., 1996a) . In contrast, although a relatively minor metabolite, MPAGa may be biologically active and capable of inhibiting IMPDH and leukocyte proliferation, and inducing cytokine release (Schutz et al., 1999; Wieland et al., 2000; Shipkova et al., 2001 ).
MPAGe undergoes extensive biliary secretion and in the gut is hydrolysed by bacterial β-glucuronidase to reform MPA, which undergoes enterohepatic recirculation (Bullingham et al., 1996b) . Between 10-61% of the plasma MPA area under the plasma concentration versus time curve (AUC) may be due to enterohepatic recirculation, which leads to a second peak in the concentration time profile of MPA at approximately 8-12 hr following the administration of mycophenolate mofetil (the prodrug of MPA) (Bullingham et al., 1996a) .
Several studies have demonstrated a relationship between plasma MPA AUC and clinical outcomes in transplant patients. In particular, a low MPA AUC has been associated with DMD #6122 a higher incidence of organ rejection early after transplantation surgery, and a high MPA AUC with drug toxicity (Pillans et al., 2001; Kuypers et al., 2003) . Hence, interactions affecting MPA AUC are likely to be clinically significant.
An important interaction has been described between cyclosporine (CsA) and MPA, with
CsA decreasing plasma concentrations of MPA (Smak Gregoor et al., 1999; Filler et al., 2001; Brown et al., 2002; Kuypers et al., 2003) . Most pharmacokinetic interactions involving calcineurin inhibitors arise from their actions as substrates for intestinal and hepatic p-glycoprotein and the cytochrome P450 3A enzymes (Bohme et al., 1993; Lin and Lu, 1998) . However, CsA may also inhibit the UGT-catalysed metabolism of MPA (Zucker et al., 1999) as well as the hepatic canalicular transporter MRP2/Mrp2 (Kobayashi et al., 2004; Hesselink et al., 2005) and the hepatic basolateral transporters of the OATP/oatp family (Shitara et al., 2002; Shitara et al., 2003) . van Gelder et al have studied the pharmacokinetic interactions between MMF and CsA in Lewis rats and Wistar TR -rats which lack the Mrp2 transporter ( van Gelder et al., 2001; Hesselink et al., 2005) . Control Lewis rats treated with MMF alone had significantly higher MPA AUC 0-24hr than Lewis rats co-administered CsA for up to 2 weeks. These differences were mainly due to a reduction in MPA exposure associated with the loss of the second peak in plasma MPA concentrations dose interval profiles, suggesting reduced enterohepatic recirculation in rats co-administered CsA. In addition, the MPAGe AUC 0-24hr for Lewis rats co-administered CsA was significantly higher than that for control Lewis rats, suggesting inhibition of the biliary secretion of MPAGe by CsA (van Gelder et al., 2001 ). In the Wistar TR -rats CsA treatment had no effect on MPAGe AUC 0-24hr , supporting the involvement of Mrp2 in the CsA-MPA interaction. However, even in TR 
Liver Perfusions
The studies were approved by the animal ethics committees of The Queen Elizabeth
Hospital and the University of South Australia (Institute of Medical and Veterinary Science). Male Wistar rats (214-350 g) were anaesthetized with an intraperitoneal injection of pentobarbital (60 mg/kg). Livers were perfused in situ as previously described (Sallustio et al., 1996) at 37ºC within a thermostatically controlled perfusion cabinet. The perfusion medium was a Krebs-bicarbonate buffer (0.30 L, pH 7.4) containing glucose (3.27 g/L), sodium taurocholate (0.896 g/L) and continually gassed with carbogen (5% CO 2 , 95% O 2 ). With a recirculating design, the perfusion medium was pumped at 30 ml/min into the liver through a cannula inserted into the hepatic portal vein and returned via a cannula inserted into the vena cava via the right atrium. Perfusion medium was sampled directly from the reservoir while bile was sampled via a cannula inserted into the bile duct. A continuous infusion of sodium taurocholate (15 µmol/hr) into the perfusion reservoir was used to promote bile flow. Each liver was assessed for viability by measuring bile flow (>5 µl/min) and monitoring liver oxygen consumption.
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The general appearance of the liver was also monitored to ensure adequate perfusion was taking place. The liver was equilibrated for between 15-20 min before a bolus dose of MPA (1.5 mg) was added to the perfusion medium (time = 0).
The hepatic disposition of MPA was examined in control Wistar rat liver perfusions (n=6). In a further separate set (n=6) of otherwise identical perfusions, CsA was added to the perfusion medium to attain an initial concentration of 250 µg/L and allowed to During each experiment, samples of the perfusion medium (1mL) were collected from the reservoir before and at 2. 5, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80 
Analytical Methods
Concentrations of MPA and MPAGe in perfusate, bile and liver samples were determined by HPLC (Westley et al., 2005) . Briefly, 100 µL of each sample were added to 250 µL of acetonitrile containing the internal standard carboxy butoxy ether mycophenolic acid (10 mg/L), vortex mixed, centrifuged (5 min @ 13000g) and the supernatant was analysed by reversed phase HPLC with UV detection at a wavelength of 254 nm. The limits of quantification for MPA and MPAGe were 0.5 and 5.0 mg/L, respectively. Due to the small quantity of pure MPAGa available, concentrations of MPAGa were determined using the calibration curve for MPA. Using samples spiked with pure MPAGa the intraassay reproducibility (CV%) and accuracy (bias%) of this method was 0.77% and -4.37%, respectively at 100 mg/L and 7.35% and 9.47%, respectively at 2.5 mg/L (n=6).
Pharmacokinetic Analysis
The half-life (t ½ ) of MPA was determined by regression analysis of the terminal portion For each liver the total clearance (CL) of MPA from perfusate was calculated as:
where D is the dose of MPA added to the perfusion reservoir. The hepatic extraction ratio (E H ) was calculated as:
where Q is perfusate flow rate (30 ml/min). 
RESULTS
Mean ± sd rat weights were 229.2 ± 50.0, 295.7 ± 25.5 and 275.5 ±29.6 g in control, TR -and MPA-CsA perfusions, respectively. Liver weights were 14.3 ± 2.4, 15.0 ± 0.9 and 12.9 ± 1.7 g in control, TR -and MPA-CsA perfusions, respectively. There was no significant difference in rat and liver weights between the three groups. Bile flow rates and oxygen consumption in the three groups of perfusions are shown in Figure 1 . There were no differences in bile flow rates between control and MPA-CsA groups (p>0.05) and bile flow remained >5 µl/min throughout the 90 min perfusion. In contrast, the bile flow rates in the TR -group were significantly lower compared to the control group (p<0.01), consistent with previous reports (Xiong et al., 2000) . Although bile flow rate was reduced in the TR -group, liver oxygen consumption was similar to that of controls (p>0.05) and all livers appeared to be fully perfused.
MPA's CL, E H , CL MPA→MPAGa and CL MPA→MPAGe were significantly lower (p<0.05) in TR -livers compared to controls whilst the t ½ of MPA was significantly longer (p<0.05) in the TR -group (Table 1 ). In addition, in the TR -group, MPAGe excretion into bile was < 1% of that in the control group and MPAGa excretion was 28% of that in the control group (Table 2) . Whilst, in the control group most of the MPA dose was recovered in bile as MPAGe, in the TR -group 59% of the MPA dose was recovered in the perfusate as MPAGe (Fig. 2, Table 2 ). In TR -livers significantly more MPA was recovered unmetabolised compared with control livers (Table 2 ). The mean total dose recovered in the control rats (89.5 ± 9.2%) was significantly different to the TR -group (67.7 ± 11.9%) (p<0.01) ( Table 2 ).
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DISCUSSION
The complete lack of biliary secretion of MPAGe in TR -rats compared to the 84% recovery of the MPA dose as MPAGe in bile in control rats suggest that Mrp2 is responsible for the transport of MPAGe from the liver into bile. This is consistent with the findings of Kobayashi et al (2004) . Whilst the excretion of MPAGa was also significantly lower in TR -rat liver perfusions, the reduction was much less than that observed for MPAGe ( Table 2 The appearance of MPAGe in the perfusate medium of TR -rats (accounting for 59% of the MPA dose) compared to less than 1% of the MPA dose as MPAGe in the control rats is consistent with the loss of Mrp2 in the mutant rats. It has been previously reported that the loss of Mrp2 protein expression in TR -rats is associated with increased expression of Mrp3 on the hepatocyte basolateral membrane (Soroka et al., 2001 ) and this may facilitate the efflux of MPAGe from the liver into perfusate. Xiong et al (2000) have also ug/L), respectively (Bohme et al., 1993; Kamisako et al., 1999) . These values are all at least an order of magnitude greater than the perfusion medium concentration of CsA used in this study and, thus, may account for the relatively modest effects of CsA.
Nevertheless, the approximately 17.5% lower recovery of MPAGe in the presence of CsA observed in this study was similar to the previously reported 20% lower biliary excretion of MPA glucuronide metabolites in Wistar rats co-administered a single dose of CsA compared to controls receiving MPA alone (Kobayashi et al., 2004) .
Whilst CsA appeared to inhibit the glucuronidation of MPA, there was no difference between control and MPA-CsA groups in the t ½ , AUC (0-∞) , CL, E H and CL int of MPA.
This is consistent with MPA behaving as a high clearance drug (E H >90%) in the isolated perfused rat liver model, so that perfusate flow rate would be the primary determinant of MPA CL. Interestingly, in both TR -rats and MPA-CsA rats, the total MPA dose recovered was significantly lower compared to controls ( Table 2) . As all three experimental groups attained the same initial MPA concentrations in perfusate ( Fig. 2A) , the lower total dose recoveries in TR-rats and MPA-CsA rats compared to controls may indicate that in these two groups a greater fraction of the dose was metabolised to the glucoside conjugate or oxidative metabolite which are both undetectable by our current analytical method.
Although in vivo studies in rats and humans suggest that, with long-term exposure, CsA inhibits the enterohepatic recirculation of MPA, the high Ki values previously reported for inhibition of Mrp2 and our present results suggest that direct inhibition of Mrp2 by
CsA may be relatively modest. In particular, the unbound concentrations of CsA achieved clinically are likely to be much lower than those attained in this study or the Ki values for This article has not been copyedited and formatted. The final version may differ from this version. (AM1) rather than parent CsA (Kohlhaw et al., 1994) . Some CsA metabolites may also undergo further metabolism to glucuronide conjugates (Sewing et al., 1990) , which may also be involved in the CsA-MPA interaction. Moreover, long term CsA exposure may also alter canalicular transporter expression or localisation, as recently reported for BSEP (Roman et al., 2003) . Importantly, the observation of a lower plasma MPA/MPAGe AUC ratio in TR -rats treated with cyclosporin compared to TR -rats treated with vehicle only (Hesselink et al., 2005) , suggests that Mrp2 independent mechanisms may also be involved in the long-term interaction between CsA and MPA.
In conclusion, we have demonstrated that Mrp2 is the transporter associated with the biliary excretion of MPAGe. The biliary excretion of MPAGa appears to be mediated by Mrp2 and another, as yet unidentified, transporter. We have also shown that, in addition to possible inhibition of Mrp2, CsA may also inhibit the hepatic glucuronidation of MPA in Wistar rats. However, following acute exposure to CsA, both of these effects were relatively modest and further work is necessary to elucidate the effects of long-term exposure to CsA on the hepatic disposition of MPA.
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